98%
921
2 minutes
20
Background: Suboptimal patient-provider relationship is a significant contributor to healthcare disparities. Minority populations report fewer favorable interactions, which may lead to poorer outcomes and engagement in care. Patients with chronic diseases are especially at risk.
Aims: We aimed to study perceptions of healthcare providers and experience among those with cirrhosis.
Methods: The nationally representative database, All of Us, was queried. The primary outcome was "favorable healthcare experiences," defined as whether providers asked for opinions, demonstrated respect, and were easy to understand. The secondary outcome was "unfavorable healthcare experiences," defined as whether patients felt they were treated with less courtesy, received poorer service, or not listened to. We compared the experience between income levels and other demographic variables. Multivariable logistic regression was adjusted for a priori covariates.
Results: 5753 patients with cirrhosis were included with a mean age of 58. The majority were male (51%), White (52%), and US-born (84%). On multivariable analysis, compared to those earning > $150 k annually, participants with $10-35 k and < $10 k reported significantly lower odds of finding providers easy to understand (OR 0.40 [0.17-0.96] and OR 0.37 [0.15-0.94], respectively) and higher odds of feeling they were treated with less courtesy (OR 3.10 [1.06-9.03] and OR 4.13 [1.30-13.1], respectively). After further controlling for education, participants with an annual income of $10-35 k and < $10 k still reported higher odds of feeling they received poorer service than others (OR 3.87 [1.09-13.71] and OR 5.01 [1.26-19.8], respectively). Compared to men, women felt that they were not listened to (OR 1.90 [1.37-2.63]).
Conclusion: Patients with cirrhosis from various backgrounds report significantly different experiences with providers. Notably, those with lower income endorsed more unfavorable interactions. We identified areas for interventions to strengthen the patient-provider relationship among patients with chronic liver disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10620-025-09374-4 | DOI Listing |
Gut Liver
September 2025
Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
Background/aims: Despite medical advances in recent decades, the mortality rate of advanced liver cirrhosis remains high. Although liver transplantation remains the most effective treatment, candidate selection is limited by donor availability and alcohol abstinence requirements. Bone marrow-derived mesenchymal stem cell (BM-MSC) transplantation has shown promise for the treatment of advanced cirrhosis.
View Article and Find Full Text PDFGut Liver
September 2025
Department of Liver Diseases, The Research Center for Hepatitis and Immunology, National Institute of Global Health and Medicine, Japan Institute for Health Security, Ichikawa, Japan.
Hepatitis C virus (HCV) clearance markedly reduces the risk of hepatocellular carcinoma (HCC); however, HCC continues to develop in a subset of patients, particularly in those with advanced fibrosis or cirrhosis. Leading hepatology societies, including Asian Pacific Association for the Study of the Liver, European Association for the Study of the Liver, American Association for the Study of Liver Diseases, Korean Association for the Study of the Liver, Taiwan Association for the Study of the Liver, and Japan Society of Hepatology, have issued divergent guidelines for HCC surveillance after sustained virologic response, which reflects variations in regional patient populations, healthcare infrastructure, and policy priorities. While traditional risk stratification primarily centers on histological staging of fibrosis, an array of additional host-related factors, including age, sex, alcohol use, metabolic comorbidities, and genetic and epigenetic profiles, further influence individual HCC risks.
View Article and Find Full Text PDFPediatr Transplant
November 2025
D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
Background: Fontan-associated liver disease can progress to advanced fibrosis, raising the potential need for combined heart-liver transplantation (CHLT) in selected patients. However, the benefits of CHLT over isolated orthotopic heart transplantation (HT), particularly in terms of mortality, remain uncertain. In this systematic review, we compared mortality outcomes following CHLT versus HT in patients with Fontan circulation, with the aim of supporting clinical decision-making.
View Article and Find Full Text PDFTher Adv Respir Dis
September 2025
Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Background: Hermansky-Pudlak syndrome (HPS) is a rare disease characterized by excessive bleeding, oculocutaneous albinism, and pulmonary fibrosis (PF). However, few studies have systematically summarized the clinical characteristics of HPS.
Objectives: To summarize the clinical characteristics, risk factors of PF, radiological and pathological presentations, and prognostic factors in patients with HPS.
Clin Nucl Med
September 2025
Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Hepatocellular carcinoma is one of the leading causes of cancer-related death worldwide. Immune checkpoint inhibitors (ICI) have improved progression and overall survival in patients progressing on sorafenib therapy. But activation of the immune system can lead to numerous immune-related adverse events.
View Article and Find Full Text PDF